These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38415094)

  • 1. Evaluation of intravenous amoxicillin-clavulanate use in two Canadian hospitals.
    Wong M; Malhotra S; Afra K
    Antimicrob Steward Healthc Epidemiol; 2024; 4(1):e24. PubMed ID: 38415094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate.
    Lipsky BA; Giordano P; Choudhri S; Song J
    J Antimicrob Chemother; 2007 Aug; 60(2):370-6. PubMed ID: 17553812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.
    Siami FS; LaFleur BJ; Siami GA
    Clin Ther; 2002 Jan; 24(1):59-72. PubMed ID: 11833836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
    Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
    Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study evaluating intravenous amoxicillin-clavulanate as an alternative to piperacillin-tazobactam for general surgery patients.
    Drost SA; Rajakumar I; Rennert-May E
    Antimicrob Steward Healthc Epidemiol; 2023; 3(1):e43. PubMed ID: 36960092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of amoxicillin-clavulanate, ampicillin-sulbactam and piperacillin-tazobactam against strains of Escherichia coli and proteus mirabilis harbouring known beta-lactamases.
    Gatermann S; Marre R
    Infection; 1991; 19(2):106-9. PubMed ID: 1646771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Gyssens IC; Dryden M; Kujath P; Nathwani D; Schaper N; Hampel B; Reimnitz P; Alder J; Arvis P
    J Antimicrob Chemother; 2011 Nov; 66(11):2632-42. PubMed ID: 21896561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Escherichia coli isolates with TEM-1 beta-lactamase to combinations of BRL42715, tazobactam or clavulanate with piperacillin or amoxycillin .
    Livermore DM; Seetulsingh P
    J Antimicrob Chemother; 1991 Jun; 27(6):761-7. PubMed ID: 1669013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the appropriateness of intravenous amoxicillin/clavulanate prescription in a teaching hospital.
    Artoisenet C; Ausselet N; Delaere B; Spinewine A
    Acta Clin Belg; 2013; 68(2):81-6. PubMed ID: 23967713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
    Akova M; Yang Y; Livermore DM
    J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clavulanate induces expression of the Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin.
    Lister PD; Gardner VM; Sanders CC
    Antimicrob Agents Chemother; 1999 Apr; 43(4):882-9. PubMed ID: 10103195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.
    Shlaes DM; Baughman R; Boylen CT; Chan JC; Charan NB; Cormier YC; Erickson A; Grossman R; Kirmani N; Suh B
    J Antimicrob Chemother; 1994 Oct; 34(4):565-77. PubMed ID: 7868408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R; Hernández-Oliva G; Cruz-Alcázar J; Amábile-Cuevas CF; Arvis P; Reimnitz P; Bogner JR;
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
    Klepser ME; Marangos MN; Zhu Z; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 1997 Feb; 41(2):435-9. PubMed ID: 9021203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of piperacillin/tazobactam in skin and soft tissue infections.
    File TM; Tan JS
    Eur J Surg Suppl; 1994; (573):51-5. PubMed ID: 7524796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.